Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00093314
Status:
WITHDRAWN
Last Update Posted:
2015-04-21
First Post:
2004-10-06
Brief Title:
HuMax-CD20 in Chronic Lymphocytic Leukemia
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
An Open-labeled International Multicenter Dose Escalating Phase III Trial of HuMax-CD20 a Fully Human Monoclonal Anti-CD20 Antibody in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Status:
WITHDRAWN
Status Verified Date:
2007-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Acquired asset
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this trial is to determine the safety and efficacy of HuMax-CD20 as a treatment for Chronic Lymphocytic Leukemia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None